The company unveiled forthcoming products for high-throughput molecular testing, diagnostic lab informatics, and microbiology automation.

The one-year projects aim to create computational tools, algorithms, visualizations, and benchmark datasets for use with Human Cell Atlas data.

Conducting studies on Latina and African-American women produces population-specific insights on the genetics of the disease that aren't possible to glean in European-heavy GWAS.

In a training subset of the larger cohort, the company was able to develop classifiers that detected many cancers while minimizing false positives.

In a rapidly growing industry where 14 new genetic tests are launched daily, tracking utilization and payment is increasingly difficult, Concert Genetics' report says.

The FDA approved its use with tissue or plasma biopsies, giving clinicians a non-invasive option to conduct a test that provides results in a day.

Presentations largely reflected negatively on the utility of PD-L1 for stratifying response, but pivotal new data on tumor mutational burden as assessed by Foundation Medicine's genomic sequencing panel.

Plenary session Chairwoman Elaine Mardis said the presentations made it clear how great the need is for interdisciplinary science as data becomes ever more complex.

Freenome will leverage proteomics firm Biognosys' technology to add protein quantification to the development of Freenome's first commercially available screening test.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more. 

This case study shows how the University Medical Center (UMC)
Utrecht Genetics Department built a foundation to efficiently transition to
whole genome sequencing with combined CNV and SNV analysis on the
same data set.

The foundry model is poised to fundamentally transform the biotechnology sector. As it revolutionized the semiconductor industry in the mid 1980’s, the foundry model brings to molecular diagnostic companies a method to leverage the commonality of manufacturing techniques. By joining common manufacturing processes across several companies, assay manufacturing becomes a variable cost versus a fixed cost with substantial benefits to assay developers.

With increased biomarker and specialty lab data being incorporated into FDA submissions, drug developers are running into challenges as they prepare data that comply with new regulatory requirements. Precision for Medicine's experts present a case study for addressing these challenges and provide a solution.